| Lori Friedman |
Lori Friedman is a Director at Project Scientist and NextRNA Therapeutics, Inc. She is also the Chief Scientific Officer at Oric Pharmaceuticals, Inc. Previously, she worked as an Independent Director at Jiya Acquisition Corp. and as the Head-Translational Oncology at Genentech, Inc. Friedman holds a doctorate degree from the University of California, Berkeley. |
| Matthew Panuwat |
Matthew Panuwat is currently the Chief Business Officer at Oric Pharmaceuticals, Inc. He previously worked as the Head of Business Development at Medivation LLC and as the Senior Vice President of Business Development at Prothena Corp. Plc. Mr. Panuwat holds an MBA from the University of California, Los Angeles, an undergraduate degree from Santa Clara University, and a graduate degree from Georgetown University. |
| Dominic Piscitelli |
Dominic Piscitelli is currently an Independent Director at Celyad Oncology SA since 2020 and the Chief Financial Officer at Oric Pharmaceuticals, Inc. since 2019. Previously, he held positions such as Director-Collaborations & Operations Finance at Astellas Pharmaceuticals SA from 2011 to 2012, Vice President-Treasury & Management Finance at OSI Pharmaceuticals, Inc. from 2009 to 2011, Chief Financial Officer at AnaptysBio, Inc. from 2017 to 2019, and VP-Finance, Strategy & Investor Relations at Medivation LLC (California) from 2012 to 2017. Mr. Piscitelli obtained his undergraduate degree and MBA from Hofstra University. |
| Edna Chow Maneval |
Edna Chow Maneval is currently the Senior Vice President-Clinical Development at Oric Pharmaceuticals, Inc. She previously held positions as Vice President-Clinical Development at Aragon Pharmaceuticals, Inc., Seragon Pharmaceuticals, Inc., and. Senior Vice President-Clinical Development at Ignyta, Inc. Dr. Maneval obtained a doctorate degree from the University of Southern California. |
| Pratik S. Multani |
Pratik S. Multani is currently an Independent Director at Chimerix, Inc. and Erasca, Inc. He is also a Principal at the American Board of Internal Medicine. In the past, he held positions such as Chief Medical Officer at Oric Pharmaceuticals, Inc., Senior Director-Medical Research & Development at Biogen, Inc., Vice President-Clinical Development at Kalypsys, Inc., Vice President-Clinical Development at Salmedix, Inc., and Chief Medical Officer at Kanisa Pharmaceuticals, Inc. He has also worked at Harvard University, The General Hospital Corp., Fate Therapeutics, Inc., and Ignyta, Inc. Dr. Multani received his undergraduate degree from Yale University, his doctorate from Harvard Medical School, and his graduate degree from Harvard T.H. Chan School of Public Health. |
| Richard A. Heyman |
Richard A. Heyman is the founder of Syndax Pharmaceuticals, Inc. (founded in 2005), X-Ceptor Therapeutics, Inc. (founded in 1999), Aragon Pharmaceuticals, Inc. (founded in 2009), Seragon Pharmaceuticals, Inc. (founded in 2013), Metacrine, Inc. (founded in 2014), and Oric Pharmaceuticals, Inc. (founded in 2014). He held various titles at these companies, including Director, Chief Scientific Officer & Senior VP-Research, President, CEO, Head-Research & Development, and President, Chief Executive Officer & Director. Dr. Heyman's current job(s) include Vice Chairman-Trustees Board at The Salk Institute for Biological Studies (since 2015), Chairman at PMV Pharmaceuticals, Inc. (since 2020), Chairman at Enliven Therapeutics, Inc. (since 2023), Director at BIOCOM, Amunix, Inc., Jewish Federation of Omaha, Inc., American Association For Cancer Research Foundation, Yumanity, Inc., and Vividion Therapeutics, Inc. He is also a Venture Partner at ARCH Venture Partners LLC and an Advisor at aTyr Pharma, Inc. He is a Member-Board of Visitors at Moores Cancer Center. Dr. Heyman's former job(s) include Chairman at Amunix Pharmaceuticals, Inc., Chairman at Rayzebio, Inc. (from 2022 to 2024), Independent Director at Receptos LLC (from 2014 to 2015), Independent Director at Organovo Holdings, Inc. (from 2013 to 2016), Independent Director at Gritstone bio, Inc. (from 2015 to 2022), Director at Yumanity Holdings LLC, Director at Mavupharma, Inc. (in 2017), Director at Millendo Therapeutics, Inc., Independent Director at BCTG Acquisition Corp., and Independent Director at Yumanity Therapeutics, Inc. (from 2016 to 2022). He also served as Vice President-Research at Ligand Pharmaceuticals, Inc. and Senior Vice President-Drug Discovery at Kalypsys, Inc. (from 1999 to 2006). Dr. Heyman's education includes an undergraduate degree from the University of Connecticut and a doctorate degree from the University of Minnesota. |
| Jacob M. Chacko |
Jacob M. Chacko is currently the President, Chief Executive Officer & Director at Oric Pharmaceuticals, Inc. He is also the Chairman at Bright Peak Therapeutics AG and Bright Peak Therapeutics, Inc. Additionally, he serves as a Director at Arog Pharmaceuticals, Inc. and as an Independent Director at 4D Molecular Therapeutics, Inc. In his former positions, Dr. Chacko worked as a Director at RentPath LLC from 2011 to 2014. He also held the position of Director at Envision Rx Options Holdings, Inc. Furthermore, he served as an Independent Non-Executive Director at Turning Point Therapeutics, Inc. from 2018 to 2021. Dr. Chacko was a Director at Lucile Salter Packard Children's Hospital at Stanford from 2013 to 2017 and at Envision Pharmaceutical Services LLC from 2013 to 2014. He briefly served as a Director at Bonti, Inc. and Packard Children's Health Alliance in 2018. Additionally, he worked as the Chief Financial Officer at Ignyta, Inc. from 2014 to 2018 and as a Vice President at TPG Capital LP from 2008 to 2014. Dr. Chacko's education includes a graduate degree from the University of Oxford, an undergraduate degree from the University of Southern California, a doctorate degree from the University of California, Los Angeles, and an MBA from Harvard Business School. |
| Lori Anne Kunkel |
Lori Anne Kunkel is currently an Independent Director at Nurix Therapeutics, Inc., Oric Pharmaceuticals, Inc., K36 Therapeutics, Inc., and Enliven Therapeutics, Inc. She is also the Owner of Lak505, LLC. Previously, Dr. Kunkel held positions such as Associate Director-Clinical Development at Chiron Corp., Independent Director at Curis, Inc., Director at Tocagen, Inc., Director at Loxo Oncology, Inc., Director at Amphivena Therapeutics, Inc., Director at Harpoon Therapeutics, Inc., Director at Maverick Therapeutics, Inc., Head-Clinical Scientist at Genentech, Inc., Chief Medical Officer at Pharmacyclics LLC, Vice President-Medical Affairs at Genitope Corp., Vice President-Clinical Development at Xencor, Inc., Chief Medical Officer at Syndax Pharmaceuticals, Inc., Chief Medical Officer at Proteolix, Inc., and Chief Medical Officer at ACT Biotech, Inc. She also held positions at Onyx Pharmaceuticals, Inc., XOMA Corp., ZymoGenetics, Inc., Salmedix, Inc., and DNAX Research, Inc. Additionally, she was a Member of the Bone Marrow Transplant Unit at the University of California. Dr. Kunkel obtained a doctorate degree from the University of Southern California and an undergraduate degree from the University of California San Diego. |
| Mardi C. Dier |
Mardi C. Dier is currently an Independent Director at Oric Pharmaceuticals, Inc., Prelude Therapeutics, Inc., and Synthekine, Inc. They are also an advisor at Healthcare Royalty Management LLC. In addition, Ms. Dier is the Chief Financial Officer & Senior Vice President at Madrigal Pharmaceuticals, Inc. Their former positions include being a Director at Futures Strategic Trust and Jewish Vocational Service, Inc., a Director-Investment Banking at Prudential Securities and Prudential Equity Group LLC, an Independent Director at Adamas Pharmaceuticals LLC, and the Vice President-Investor Relations at Chiron Corp. They also served as the CFO, Chief Business Officer & Executive VP at Portola Pharmaceuticals LLC and the Chief Financial Officer & Executive Vice President at Ultragenyx Pharmaceutical, Inc. Ms. Dier started their career as a Senior Accountant at KPMG LLP and KPMG Peat Marwick LLP. They also briefly served as the Chief Business Officer at ACELYRIN, Inc. Ms. Dier obtained their undergraduate degree from Stanford University in 1986 and an MBA from UCLA Anderson School of Management in 1992. |
| Steven L. Hoerter |
Steven L. Hoerter is currently the President, Director & Chief Executive Officer at Deciphera Pharmaceuticals LLC. He is also the President, Chief Executive Officer & Director at Deciphera Pharmaceuticals, Inc. Additionally, he serves as an Independent Director at Oric Pharmaceuticals, Inc. Previously, Mr. Hoerter held positions as the Director-Pipeline Development at Genentech, Inc. from 2005 to 2010. He was an Independent Director at Constellation Pharmaceuticals, Inc. from 2018 to 2021, and also served as an Independent Director at Constellation Pharmaceuticals, Inc. from 2016 to 2018. He was an Independent Director at Ignyta, Inc. from 2016 to 2018. From 2016 to 2019, he served as the Chief Commercial Officer at Agios Pharmaceuticals, Inc. . Mr. Hoerter has also worked at Roche Group as the GM, Head-Sub-Saharan Africa & Indian Ocean Region. He was the Chief Commercial Officer & Executive VP at Clovis Oncology, Inc. from 2015 to 2016. In terms of education, Mr. Hoerter holds an MBA from the University of Tilburg, an undergraduate degree from Bucknell University, and a graduate degree from Purdue University. |
| Angie J. You |
Angie J. You is currently an Independent Director at Oric Pharmaceuticals, Inc., a Senior Advisor at Frazier Management LLC, and an Advisor at Casdin Capital. Previously, she served as the Chief Executive Officer & Director at Amunix Pharmaceuticals, Inc. from 2018 to 2022. She also held positions as a Director of Business Development at Exelixis, Inc., Senior Director of Lifecycle Management at Orexigen Therapeutics, Inc., and Director at Rayzebio, Inc. from 2022 to 2024. Dr. You was a Vice President at Venrock Associates from 2005 to 2007 and the Chief Business & Strategy Officer at Sierra Oncology, Inc. from 2014 to 2018. She has also worked as the Chief Operating Officer at Ren Pharmaceuticals, Inc. and the Chief Business Officer at Synosia Therapeutics AG. Additionally, she has experience as a Management Consultant at McKinsey & Co., Inc. and as the Chief Business Officer at Aragon Pharmaceuticals, Inc. from 2010 to 2013. Dr. You holds graduate and doctorate degrees from Harvard University and an undergraduate degree from Harvard College. |
